The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rule 8.3- CARECAPITAL GROUP PLC

29 May 2009 16:25

RNS Number : 0663T
Amarate Limited
29 May 2009
 



  FORM 8.3

DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE 

(Rule 8.3 of the Takeover Code)

1. KEY INFORMATION

Name of person dealing  (Note 1)

AMARATE LIMITED

Company dealt in

CARECAPITAL GROUP PLC

Class of relevant security to which the dealings being disclosed relate (Note 2)

1P ORDINARY

Date of dealing

MAY 29, 2009

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long

Short

Number (%)

Number (%)

(1) Relevant securities 

1,395,834   1.82%

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

1,395,834 1.82%

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

Number (%)

Number (%)

(1) Relevant securities 

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

(c) Rights to subscribe (Note 3)

Class of relevant security:

Details

3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale

Number of securities

Price per unit (Note 5)

(b) Derivatives transactions (other than options)

Product name, 

e.g. CFD

Long/short (Note 6)

Number of securities (Note 7)

Price per unit (Note 5)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise

price 

Type, e.g. American, European etc.

Expiry 

date

Option money

paid/received per unit (Note 5) 

(ii) Exercising

Product name, e.g. call option

Number of securities 

Exercise price per unit (Note 5)

(d) Other dealings (including new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

Transfer (receipt) for nil consideration

Receipt of 1,395,834 1p ordinary shares for nil consideration 

0

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

NONE

Is a Supplemental Form 8 attached? (Note 9) NO

Date of disclosure

MAY 29, 2009

Contact name

Andrew Holdsworth

Telephone number

+41 58 705 3404

If a connected EFM, name of offeree/offeror with which connected

If a connected EFM, state nature of connection (Note 10)

Notes

The Notes on Form 8.3 can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETBUGDUDDDGGCC
Date   Source Headline
27th Aug 20197:00 amRNSTotal Voting Rights and Directors' Shareholdings
8th Aug 201910:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Nearing the end-goal
7th Aug 20197:00 amRNSIssue of equity and new debt facility
6th Aug 201911:05 amRNSSecond Price Monitoring Extn
6th Aug 201911:00 amRNSPrice Monitoring Extension
25th Jul 20195:12 pmRNSResult of AGM
25th Jul 20197:00 amRNSAGM Statement & Technological update
22nd Jul 20197:00 amRNSHarley Street update
28th Jun 20197:00 amRNSFinal Results
3rd Jun 20197:00 amRNSTechnological update
31st May 20195:30 pmRNSTotal Voting Rights
17th May 20195:29 pmRNSHolding(s) in Company
16th May 20192:23 pmEQSAdvanced Oncotherapy (AVO-GB): Strong fundamentals underpin future growth
13th May 201912:20 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Commercialising a breakthrough technology
10th May 20197:00 amRNSDebt facility secured
16th Apr 201910:26 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Preparing for commercialisation
16th Apr 20199:12 amEQSAdvanced Oncotherapy (AVO-GB): Key talent acquisition reaffirms the promise of LIGHT
16th Apr 20197:00 amRNSSenior Management Appointment
7th Mar 20199:00 amRNSPrice Monitoring Extension
22nd Feb 20197:00 amRNSGrant of options
1st Feb 20197:00 amRNSAppointment of Nominated Adviser and Joint Broker
30th Jan 201911:45 amRNSSchedule 2(g) Disclosure
29th Jan 20199:38 amRNSTotal Voting Rights and Significant Shareholdings
24th Jan 201912:14 pmRNSSchedule 2(g) Disclosure
22nd Jan 20193:29 pmRNSResult of General Meeting
21st Jan 201911:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Important regulatory milestone: ISO approval
21st Jan 20197:00 amRNSISO 13485:2016 certification for medical devices
21st Dec 201810:15 amRNSLaunch of 2018 SAYE Scheme
21st Dec 20187:00 amRNSProposed Direct Subscription to raise £10.0m
16th Oct 20184:31 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated
16th Oct 20183:58 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
10th Oct 20187:30 amRNSGPSL Research - Flash Note on AVO
10th Oct 20187:00 amRNSTechnological update
4th Oct 201811:07 amRNSGPSL Research - Flash Note on AVO
28th Sep 20187:00 amRNSHalf-year Report
27th Sep 20187:00 amRNSTechnological update
10th Sep 201811:32 amRNSHolding(s) in Company
7th Sep 201811:52 amRNSHolding(s) in Company
3rd Sep 20185:15 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
3rd Sep 201811:38 amRNSCompletion of the £6.41m Placing
29th Aug 20189:57 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
28th Aug 20187:00 amRNSDirector Declaration
9th Aug 20187:00 amRNSExercise of Warrants and Issue of Shares
2nd Aug 20187:00 amRNS£6.41m Placing
25th Jul 20183:34 pmRNSResult of AGM
4th Jul 20184:40 pmRNSSecond Price Monitoring Extn
4th Jul 20184:35 pmRNSPrice Monitoring Extension
4th Jul 201811:05 amRNSSecond Price Monitoring Extn
4th Jul 201811:00 amRNSPrice Monitoring Extension
4th Jul 20189:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.